Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 9/20 | 0.58 |
| ▸ | GRM5 | P41594 | 8/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891455 | 0.85 | NOTUM (0.41) | GRM1GRM5NPC1 | |
| SCHEMBL3068738 | 0.84 | GPR119 (0.53) | GRM1GRM5GPR119NPC1 | |
| SCHEMBL19126818 | 0.83 | GPR119 (0.48) | GRM1GRM5GPR119HTTATM | |
| SCHEMBL12975585 | 0.83 | GRM1 (0.60) | GRM1GRM5GPR119HTTATM | |
| SCHEMBL2893886 | 0.79 | GPR119 (0.42) | GRM1GRM5GPR119HTTSMARCA2 | |
| SCHEMBL1583147 | 0.78 | GPR119 (0.58) | GRM1GRM5GPR119SMARCA2SMARCA4 | |
| SCHEMBL27163690 | 0.77 | KDM4E (0.43) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL8614193 | 0.76 | GRM1 (0.60) | GRM1GRM5GPR119 | |
| SCHEMBL31267751 | 0.75 | NR1H2 (0.41) | GPR119HTTATMSMARCA2SMARCA4 | |
| SCHEMBL28597591 | 0.75 | GPR119 (0.58) | GRM1GRM5GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| CN-1980901-A | Biaryl derivatives | BANYU PHARMA CO LTD (JP) | 2007-06-13 | — | — | CN | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191389-A1 | Biaryl derivatives | GRM1, GRIN1, GRIN2B | GRM1 1/4885GRM5 26/4885GPR119 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.